natgillin/translations-raw huggingface dataset:
• The solvent will be pulled into the powder vial by the vacuum contained within it. 
• Vehikel bo stekel v vialo s praškom zaradi vakuuma v viali z zdravilom.
1 vial 250 IU human coagulation factor X powder for solution for injection 1 vial 2.5 mL water for injections 
1 viala z 250 i.e. humanega koagulacijskega faktorja X, prašek za raztopino za injiciranje 1 viala z 2,5 ml vode za injekcije
1 vial 250 IU powder 1 vial 2.5 mL water for injections 1 Transfer Device (Mix2Vial) 
1 viala z 250 i.e., prašek 1 viala z 2,5 ml vode za injekcije 1 pribor za prenos vehikla (Mix2Vial)
Renal impairment No dose adjustment is necessary. 
Odmerka ni treba prilagajati.
Hypersensitivity or allergic reactions (which may include angioedema, burning and stinging at the infusion site, chills, flushing, generalised urticaria, headache, hives, hypotension, lethargy, nausea, restlessness, tachycardia, tightness of the chest, tingling, vomiting, wheezing) have been observed rarely with treatment of other haemophilias and may in some cases have progressed to severe anaphylaxis (including shock). 
navzeo, nemir, tahikardijo, stiskanje v prsih, mravljinčenje, bruhanje, sopenje) so redko opazili pri zdravljenju drugih hemofilij in so v določenih primerih lahko napredovale v hudo anafilaksijo (vključno s šokom).
It is recommended that post-infusion plasma factor X levels are measured for each patient before and after surgery, to ensure that haemostatic levels are obtained and maintained. 
Za doseganje in vzdrževanje hemostatskih ravni je priporočljivo, da se za vsakega bolnika pred operativnim postopkom in po njem izmerijo ravni faktorja X v plazmi po infundiranju.
• Connect the syringe to the clear part of the transfer device and push the air in the syringe into the vial. 
• Priključite injekcijsko brizgo na prozorni del pribora za prenos vehikla in potisnite zrak iz injekcijske brizge v vialo.
If you get any side effects, talk to your doctor, pharmacist or nurse. 
- Če opazite kateri koli neželeni učinek, se posvetujte z zdravnikom, farmacevtom ali medicinsko sestro.
1 vial 500 IU powder 1 vial 5 mL water for injections 1 Transfer Device (Mix2Vial) 
1 viala s 500 i.e., prašek 1 viala s 5 ml vode za injekcije 1 pribor za prenos vehikla (Mix2Vial)
PARTICULARS TO APPEAR ON THE OUTER PACKAGING CARTON 500 IU 
PODATKI NA ZUNANJI OVOJNINI ŠKATLA 500 i.e.
Peel back the top of the transfer device package but leave the device in the package. 
Odlepite zgornji del pakiranja pribora za prenos vehikla, vendar pustite pribor v embalaži.
For major surgery, a median of 13 infusions (range 2 to 15 infusions) and a median cumulative dose of 181 IU/kg (range 45 to 210 IU/kg) were required to maintain haemostasis. 
infuzij (od 2 do 15 infuzij) in mediani kumulativni odmerek 181 i.e./kg (od 45 do 210 i.e./kg).
Factor X is converted from its inactive form to the active form (factor Xa) by the cleavage of a 52-residue peptide from the heavy chain. 
Faktor X se iz svoje neaktivne oblike pretvori v aktivno obliko (faktor Xa) s cepljenjem
If you get any of these contact your doctor. 
Če se kateri koli od teh neželenih učinkov pojavi pri vas, se posvetujte z zdravnikom.
Step 2: Place the blue end of the transfer device on the solvent vial and push straight down until the spike penetrates the rubber stopper and snaps into place. 
2. korak: Postavite modri konec pribora za prenos vehikla na vialo vehikla in ga potisnite naravnost navzdol, da bo konica prebodla gumijasti zamašek in se zaskočila na svoje mesto.
The mean (CV%) half-life of human coagulation factor X was 30.3 (22.8) hr and clearance was 1.35 (21.7) mL/kg/hr. 
Srednja (CV %) razpolovna doba človeškega koagulacijskega faktorja X je znašala 30,3 (22,8) ur, očistek pa
For secondary prophylaxis against re-bleeding or short-term prophylaxis prior to anticipated physical activity or dental appointments: 25 IU/kg Coagadex should be injected and repeated as required. 
Za sekundarno preprečevanje ponovnih krvavitev ali za kratkotrajno preprečevanje krvavitve pred pričakovano fizično aktivnostjo ali zobozdravstvenimi posegi: injicirati je treba odmerek 25 i.e./kg zdravila
Systemic exposure to FX:C at the Repeat PK visit (at least 6 months later) was equivalent to that at baseline, since repeat/baseline ratios for all PK parameters were within the range of 90% to 110%. 
enakovredna tisti ob izhodišču, saj so bila razmerja ponovljeni/izhodiščni za vse parametre farmakokinetike v razponu od 90 % do 110 %.
Method of administration Intravenous use. 
Intravenska uporaba
Coagadex should not be used as an antidote to the effects of direct oral anti-coagulants (DOACs) in patients who do not have factor X deficiency. 
Teh protitrombotičnih zdravil se ne sme uporabljati pri bolnikih s pomanjkanjem faktorja X. Zdravila Coagadex ne smete uporabljati kot antidota za učinke neposrednih peroralnih zdravil za zaviranje strjevanja krvi pri bolnikih, ki nimajo pomanjkanja faktorja X.
Hypersensitivity reactions, allergic reactions, and anaphylaxis have not been reported in Coagadex clinical trials. 
V kliničnih preskušanjih zdravila Coagadex niso poročali o preobčutljivostnih reakcijah, alergijskih reakcijah in anafilaksiji.
Talk to your doctor, pharmacist or nurse before using Coagadex: 
Pred začetkom uporabe zdravila Coagadex se posvetujte z zdravnikom, farmacevtom ali medicinsko sestro:
Signs of these may include skin rash (including hives), tingling, flushing, nausea, vomiting, headache, cough, wheezing, tightness of the chest, chills, fast heart rate, dizziness, lethargy, restlessness, swelling of the face, tightness of the throat, discomfort at the site of injection. 
zbadanje, eritem), mrzlico, kašljem, omotico, povišano telesno temperaturo, zardevanjem, generalizirano urtikarijo, glavobolom, koprivnico, hipotenzijo, letargijo, bolečinami mišično-skeletnega sistema, navzeo, pruritusom, izpuščajem, nemirom, tahikardijo, tiščanjem v prsih, mravljinčenjem, bruhanjem, sopenjem.
• back pain 
• bolečina v hrbtu
Prophylaxis of Bleeding Episodes 
Profilaksa epizod krvavitev
Despite these measures, when medicines prepared from human blood or plasma are administered, the possibility of passing on an infection cannot be totally excluded. 
Kljub tem ukrepom ni mogoče povsem izključiti prenosa okužbe ob dajanju zdravil, pripravljenih iz človeške krvi ali plazme.
PARTICULARS TO APPEAR ON THE OUTER PACKAGING CARTON 250 IU 
PODATKI NA ZUNANJI OVOJNINI ŠKATLA 250 i.e.
Routine prophylaxis was started with unit doses of 40-50 IU/kg and during the first 6 weeks trough levels of Factor X were measured to adjust the dosage regimen to maintain a trough level of at least 5 IU/dL. 
V prvih 6 tednih so merili najnižje ravni faktorja X in skladno s tem prilagajali režim odmerjanja za vzdrževanje najnižje ravni vsaj 5 i.e./dl.
• Immediately invert the vial of solution, which will be drawn into the syringe. 
• Takoj obrnite vialo z raztopino, ki jo bo potegnilo v injekcijsko brizgo.
• Separate the empty solvent vial and blue part from the clear part by unscrewing anti-clockwise. 
• Odstranite prazno vialo vehikla in modri del s prozornega dela, tako da ju obračate v nasprotni smeri vrtenja urinega kazalca.
Certain anticoagulants including those blocking a blood clotting factor (factor Xa) should not be used in patients with factor X deficiency receiving Coagadex due to a risk of blood clots. 
Xa) se pri bolnikih s pomanjkanjem faktorja X, ki prejemajo zdravilo Coagadex, ne sme uporabljati zaradi tveganja za nastanek krvnih strdkov.
- careful selection of blood and plasma donors to make sure those at risk of carrying infections are excluded, - the testing of each donation and pools of plasma for signs of virus/infections, - the inclusion of steps in the processing of the blood or plasma that can inactivate or remove viruses. 
- vključitev korakov, ki lahko inaktivirajo ali odstranijo viruse, v obdelavo krvi ali plazme.
Frequencies have been evaluated according to the following convention: very common (≥1/10 subjects); common (≥1/100 to <1/10). 
(≥1/10 bolnikov); pogosti (≥1/100 do <1/10 bolnikov).
Coagadex to raise plasma factor X levels to 70-90 IU/dL. 
v plazmi na 70-90 i.e./dl.
1 solvent vial of 5 mL water for injections 
1 pribor za prenos vehikla 1 vialo z vehiklom s 5 ml vode za injekcije
1 solvent vial of 2.5 mL water for injections 
1 pribor za prenos vehikla 1 vialo z vehiklom z 2,5 ml vode za injekcije
Coagadex 500 IU powder and solvent for solution for injection human coagulation factor X 
Coagadex 500 i.e. prašek in vehikel za raztopino za injiciranje humani koagulacijski faktor X
What you need to know before you use Coagadex 3. 
Kaj je zdravilo Coagadex in za kaj ga uporabljamo Kaj morate vedeti, preden boste uporabili zdravilo Coagadex Kako uporabljati zdravilo Coagadex
Coagadex 250 IU powder and solvent for solution for injection human coagulation factor X 
Coagadex 250 i.e. prašek in vehikel za raztopino za injiciranje humani koagulacijski faktor X
In adults and adolescents at least 12 years of age, the expected in vivo peak increase in factor X level expressed as IU/dL (or % of normal) can be estimated using the following formulae: 
Pri odraslih in mladostnikih, starih 12 let ali več, je pričakovani največji dvig ravni faktorja X in vivo,
Dose (IU) = body weight (kg) x desired factor X rise (IU/dL or % of normal) x 0.5 OR Increase in factor X level (IU/dL or % of normal) = [total dose (IU)/body weight (kg)] x 2 
Odmerek (i.e.) = telesna masa (kg) x želeni dvig faktorja X (i.e./dl ali % običajne vrednosti) x 0,5
The study in young children (see section 5.1) measured incremental recovery at 30 min (IR30min) after the first dose and after the last dose in the study (approximately 6 months later) (see section 5.1) Combining IR30min values for FX:C at the baseline visit (n=9) and the Repeat PK assessment (n=9) gave an overall geometric mean IR of 1.74 (range 1.3-2.2) IU/dL per IU/kg administered (n=9). 
V študiji pri mladih otrocih (glejte poglavje 5.1) so merili prirastno zvečanje aktivnosti 30 minut (IR30min) po prvem odmerku in po zadnjem odmerku v študiji (približno 6 mesecev pozneje) (glejte poglavje 5.1).
Infusion site pain 
Bolečina na mestu infundiranja
Place the clear end of the transfer device on the powder vial and push straight down until the spike penetrates the rubber stopper and snaps into place. 
Položite prozorni konec pribora za prenos vehikla na vialo s praškom in ga potisnite naravnost navzdol, da bo konica prebodla gumijasti zamašek in se zaskočila na svoje mesto.
• Place the blue end of the transfer device on the solvent vial and push straight down until the spike penetrates the rubber stopper and snaps into place. 
• Postavite modri konec pribora za prenos vehikla na vialo z vehiklom in ga potisnite naravnost navzdol, da bo konica prebodla gumijasto zaporko in se zaskočila na svoje mesto.
Coagadex 500 IU 
Coagadex 500 i.e.
Coagadex 250 IU 
coagadex 250 i.e.
coagadex 250 iu 
Coagadex 250 i.e.
• tiredness 
• utrujenost
• Place the clear end of the transfer device on the powder vial and push straight down until the spike penetrates the rubber stopper and snaps into place. 
• Položite prozorni konec pribora za prenos vehikla na vialo s praškom in ga potisnite naravnost navzdol, da bo konica prebodla gumijasto zaporko in se zaskočila na svoje mesto.
How to store Coagadex 
Shranjevanje zdravila Coagadex
The following side effects have been reported with Coagadex. 
Pri zdravljenju z zdravilom Coagadex so poročali o naslednjih neželenih učinkih.
In a clinical study of Coagadex in subjects with severe or moderate factor X deficiency (basal FX:C <5 IU/dL), the pharmacokinetics of Coagadex were assessed in 16 subjects after administration of a nominal dose of 25 IU/kg. 
FX:C < 5 i.e./dl) so ocenjevali farmakokinetiko zdravila Coagadex po dajanju nominalnega odmerka
Dose (IU) = body weight (kg) x desired factor X rise (IU/dL or % of normal) x 0.6 OR Increase in factor X level (IU/dL or % of normal) = [total dose (IU)/body weight (kg)] x 1.7 
ALI Dvig ravni faktorja X (i.e./dl ali % običajne vrednosti) = [skupni odmerek (i.e.)/telesna masa (kg)] x 2
Contents of the pack and other information 
Shranjevanje zdravila Coagadex Vsebina pakiranja in dodatne informacije
Coagadex 250 IU powder and solvent for solution for injection. 
Coagadex 250 i.e. prašek in vehikel za raztopino za injiciranje Coagadex 500 i.e. prašek in vehikel za raztopino za injiciranje
Reconstitution time is less than 2 minutes. 
Čas priprave je manj kot 2 minuti.
Date of first authorisation: 23 August 2012 Date of the latest renewal: 24 April 2017 
Datum prve odobritve: 23. avgust 2012 Datum zadnjega podaljšanja: 24.april 2017
Resistant (R>) 
Rezistentni (R >)
Dry powder: 3 years 
Suhi prašek: 3 leta
A risk to the newborns/infants cannot be excluded. 
Tveganja za novorojenčka/dojenčka ni možno izključiti.
Calculated using the Cockcroft-Gault formula for adults. 
Izračunano z uporabo Cockcroft-Gaultove formule za odrasle.
Renal changes were not reversible but were reduced in severity following a 4 week recovery period. 
Ledvične spremembe niso bile reverzibilne, se je pa njihova izrazitost zmanjšala po 4-tedenskem obdobju okrevanja.
The chemical and physical in-use stability has been demonstrated for up to 24 hours at 2-8 °C. 
Kemična in fizikalna stabilnost med uporabo sta dokazani do 24 ur pri temperaturi od 2 - 8°C.
In this situation, you should not take medicines that stop or slow bowel movement. 
V takšnih okoliščinah ne smete jemati zdravil, ki ustavijo ali upočasnijo gibanje črevesa.
The hospital will dispose of any waste materials safely. 
V bolnišnici bodo varno odstranili kakršen koli odpadni material.
Overall, the safety profile in these 227 patients was similar to that observed in the adult population. 
V celoti je bil varnostni profil pri teh 227 bolnikih podoben kot so ga zabeležili v odrasli skupini bolnikov.
Frequency categories are derived according to the following conventions: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), not known (cannot be estimated from the available data). 
Kategorije pogostnosti so opredeljene po naslednjem dogovoru: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/1.000), neznana pogostnost (ni mogoče oceniti iz razpoložljivih podatkov).
• The other ingredient is arginine. 
• Druga sestavina zdravila je arginin.
• If you have kidney problems (your doctor may have to prescribe a lower dose) 
• če imate težave z ledvicami (zdravnik vam bo morda moral predpisati manjši odmerek),
If the level of your red blood cells fall your doctor may check to see if these antibodies have caused this. 
Če bo vrednost rdečih krvnih celic padla, bo vaš zdravnik morda preveril ali so to povzročila ta protitelesa.
The total time interval between starting reconstitution and completing preparation of the intravenous infusion should not exceed 30 minutes. 
Celotni čas med začetkom in koncem priprave intravenske infuzije ne sme preseči 30 minut.
Do not use this medicine during pregnancy unless your doctor has told you to. 
Tega zdravila ne uporabljajte med nosečnostjo, če vam ne naroči zdravnik.
There is limited experience in treating patients with diabetic foot infections. 
Na voljo so le omejene izkušnje pri zdravljenju bolnikov z okužbami diabetičnega stopala.
Carcinogenicity studies have not been conducted. 
Študij kancerogenosti niso izvedli.
One or more of these mechanisms may co-exist in a single bacterial isolate. 
V istem bakterijskem izolatu lahko soobstaja eden ali več teh mehanizmov.
Arginine 
arginin
• Streptococcus anginosus group (includes S. anginosus, S. intermedius, and S. constellatus) 
• Skupina Streptococcus anginosus (vključuje S. anginosus, S. intermedius in S. constellatus)
Gram-negative micro-organisms • Fusobacterium spp. 
Gramnegativni mikroorganizmi • Fusobacterium spp.
There was a 33% increase in AUC0-∞ in the elderly that was mainly attributable to age-related changes in renal function. 
Pri starejših je bila ugotovljena 33 % večja AUC0-∞; povečanje je bilo predvsem posledica s starostjo povezanih sprememb delovanja ledvic.
≥ 15 to ≤ 30 300 mg ESRD, including haemodialysis 
≥ 15 do ≤ 30 300 mg ESRD, vključno s hemodializo
Staphylococcus aureus Streptococcus pneumoniae Streptococcus Groups A, B, C, G 
Staphylococcus aureus Streptococcus pneumoniae Streptokoki skupine A, B, C, G
This test looks for certain antibodies which may act against your red blood cells. 
Ta preiskava odkriva določena protitelesa, ki lahko delujejo proti rdečim krvnim celicam.
Infusion related reactions (such as phlebitis) can be managed by prolonging the infusion duration. 
Z infuzijo povezane reakcije (kot je flebitis) je mogoče obvladati s podaljšanjem časa infundiranja.
Undesirable effects e.g. dizziness may occur and this may have an effect on the ability to drive and use of machines (see section 4.8). 
Pojavijo se lahko neželeni učinki, kot je omotica in to lahko vpliva na sposobnost vožnje in upravljanja strojev (glejte poglavje 4.8).
From a microbiological point of view, the medicinal product should be used immediately unless reconstitution and dilution has taken place in controlled and validated aseptic conditions. 
Z mikrobiološkega stališča je treba zdravilo uporabiti takoj, razen če sta bila priprava in razredčenje opravljena v nadzorovanih in preverjenih aseptičnih pogojih.
Consideration should be given to official guidance on the appropriate use of antibacterial agents. 
Upoštevati je treba uradne smernice za ustrezno uporabo zdravil za zdravljenje bakterijskih okužb.
If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8ºC, unless reconstitution/dilution has taken place in controlled and validated aseptic conditions. 
Če ni uporabljeno takoj, so čas shranjevanja med uporabo in pogoji pred uporabo odgovornost uporabnika; čas običajno ne sme presegati 24 ur na temperaturi od 2 do 8 °C, razen če je priprava/redčenje opravljena v nadzorovanih in preverjenih aseptičnih pogojih.
Overall, the adverse events reported in these studies were consistent with the known safety profile for Zinforo. 
Na splošno so bili neželeni dogodki, o katerih so poročali v teh študijah, skladni z znanim varnostnim profilom zdravila Zinforo.
Studies have shown that Zinforo solutions for infusion are stable for up to 6 hours at room temperature. 
Študije so pokazale, da so raztopine za infundiranje Zinforo na sobni temperaturi stabilne do 6 ur.
Antibacterial activity against other relevant pathogens 
Protibakterijska aktivnost proti drugim relevantnim patogenom
• If you have had severe diarrhoea whilst taking antibiotics in the past 
• če ste imeli hudo drisko ob jemanju antibiotikov v preteklosti.
The usual recommended dose for children depends on the age and weight of the child and is given every 8 or 12 hours. 
Običajen priporočeni odmerek za otroke je odvisen od otrokove starosti in telesne mase ter se uporablja na 8 ali 12 ur.
• If you are allergic to ceftaroline fosamil or any of the other ingredients of this medicine (listed in section 6). 
• če ste alergični na fosamilceftarolin ali katero koli sestavino tega zdravila (navedeno v poglavju 6),
• Diarrhoea that becomes severe or does not go away or stool that contains blood or mucus during or after treatment with Zinforo. 
• driska, ki postane huda ali ne izgine, ali blato, ki vsebuje kri ali sluz, med zdravljenjem z zdravilom Zinforo ali po njem.
When stored as recommended, the product potency is not affected. 
Če je zdravilo shranjeno, kot je priporočeno, se njegova moč ne zmanjša.
The powder must be reconstituted with water for injections and the resulting concentrate must then be immediately diluted prior to use. 
Prašek je treba pripraviti z vodo za injekcije, tako nastali koncentrat pa redčiti tik pred uporabo.
Adverse reactions are classified according to System Organ Class and frequency. 
Neželeni učinki so razvrščeni po organskih sistemih in pogostnosti.
The usual recommended dose for adults is 600 mg every 12 hours. 
Običajen priporočeni odmerek za odrasle je 600 mg na 12 ur.
Once the intravenous solution is prepared with diluents listed in section 6.6 it should be administered within 6 hours of preparation. 
Ko je intravenska raztopina pripravljena z vehikli, navedenimi v poglavju 6.6, jo je treba aplicirati v 6 urah po pripravi.
After reconstitution: The reconstituted vial should be diluted immediately. 
Po rekonstituciji Pripravljeno vialo je treba razredčiti takoj.
120/every 8 hours 
120/vsakih 8 ur
* Calculated using the Schwartz formula (in mL/min/1.73 m2) for paediatric patients. 
* Izračunano z uporabo Schwartzove formule (v ml/min/1,73 m2) za pediatrične bolnike.
Treatment of overdose should follow standard medical practice; 
Pri zdravljenju prevelikega odmerjanja je treba upoštevati standardno medicinsko prakso.
If a severe allergic reaction occurs during treament with Zinforo, the medicinal product should be discontinued and appropriate measures taken. 
Če se med zdravljenjem z zdravilom Zinforo pojavi huda alergijska reakcija, je treba uporabo zdravila prekiniti in ustrezno ukrepati.
Juvenile toxicity 
Toksičnost pri mladičih
Do not use Zinforo if any of the above applies to you. 
Ne uporabljajte zdravila Zinforo, če kaj od naštetega velja za vas.
Relative overdosing could occur in patients with moderate renal impairment. 
Relativno preveliko odmerjanje se lahko pojavi pri bolnikih z zmerno okvaro ledvic.
It is free of any particles. 
Raztopina je brez delcev.
Therefore, Zinforo should be used with caution in this patient population. 
Zato je treba zdravilo Zinforo v tej skupini bolnikov uporabljati previdno.
• More enzymes produced by your liver (as shown in blood tests) 
• večje nastajanje encimov v jetrih (to pokažejo preiskave krvi)
The European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints for susceptibility testing are presented below. 
Spodaj so prikazane mejne vrednosti za testiranje občutljivosti po EUCAST (European Committee on Antimicrobial Susceptibility Testing).
Infusion volumes for paediatric patients will vary according to the weight of the child. 
Volumen infuzije za pediatrične bolnike se razlikuje glede na otrokovo telesno maso.
You may experience fever, flu-like symptoms, sore throat, or any other infection which may be serious. 
Pojavijo se vam lahko zvišana telesna temperatura, gripi podobni simptomi, boleče žrelo ali kakšna druga okužba, ki je lahko resna.
The MAH shall perform the pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2. of the Marketing Authorisation and any agreed subsequent updates of the RMP. 
Imetnik dovoljenja za promet z zdravilom bo izvedel zahtevane farmakovigilančne aktivnosti in ukrepe, podrobno opisane v sprejetem RMP, predloženem v modulu 1.8.2 dovoljenja za promet z zdravilom, in vseh nadaljnjih sprejetih posodobitvah RMP.
The plasma protein binding of ceftaroline is low (approximately 20%) and ceftaroline is not distributed into erythrocytes. 
Vezava ceftarolina na beljakovine v plazmi je majhna (približno 20 %) in ceftarolin se ne porazdeli v eritrocite.
• Sudden swelling of your lips, face, throat or tongue; a severe rash; and, swallowing or breathing problems. 
• nenadna oteklost ustnic, obraza, žrela ali jezika, hud izpuščaj, težave s požiranjem ali dihanjem.
Patients with pre-existing seizure disorder 
Bolniki z obstoječo konvulzivno motnjo
• Redness, pain or swelling where the injection was given. 
• pordelost, bolečina ali oteklost na mestu, kjer ste dobili injekcijo
Each vial is for single use only. 
Vsaka viala je namenjena samo za enkratno uporabo.
The mean terminal elimination half-life of ceftaroline in healthy adults is approximately 2.5 hours. 
Povprečni končni razpolovni čas izločanja ceftarolina je pri zdravih odraslih približno 2,5 ure.